Monosodium urate (MSU) crystal formation, deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. These researchers examined the effects of human cartilage homogenates on MSU crystallization and MSU crystal-induced inflammation…
Tildrakizumab Promising for Psoriasis in Patients with PsA
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…
New Consensus Recommendations Guide Sjögren’s Syndrome Management
NEW YORK (Reuters Health)—New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjögren’s syndrome with topical and systemic therapies. Sjögren’s syndrome presents with a broad spectrum of clinical manifestations and autoantibodies, including antinuclear antibodies (the most frequently detected), anti-Ro/SS-A (the most specific) and cryoglobulins and hypocomplementemia (the main prognostic markers)….
Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA
Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…
Renal Transplant Outcomes in Patients with Lupus Nephritis
A recent study from Brazil suggests lupus nephritis patients who receive renal transplant have a high five-year survival rate. Researchers found the presence of venous thrombosis and antiphospholipid syndrome, but not viral infection, were important predictors of renal graft loss in these patients…
Progress on Preventing Immune-Related Adverse Events
ATLANTA—One of the hottest topics in medicine is the emerging field of cancer immunotherapy. However, immune-related adverse events (irAEs) are associated with the therapy, and when things go wrong, they can go very, very wrong, said Ryan Sullivan, MD, during the 2019 ACR/ARP Annual Meeting in November. “The guiding principle of cancer immunotherapy is [that]…
A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis
ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting…
New Draft Gout Guideline Released
ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…
Year in Review: Rheumatic Disease Research in 2019
ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…
Atmospheric & Environmental Changes Tied to Organ-Specific Lupus Flares
NEW YORK (Reuters Health)—Changes in atmospheric and environmental factors may contribute to organ-specific disease exacerbation in patients with systemic lupus erythematosus (SLE), according to a new study. The study found “strong associations between atmospheric variables and fine particulate matter concentration over the 10 days prior to a patient visit and organ-specific lupus flares at the…
- « Previous Page
- 1
- …
- 107
- 108
- 109
- 110
- 111
- …
- 342
- Next Page »